Add BrightSurf on Google Email

Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy

Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.

Alliance study shows new promise against locally advanced lung cancer

A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...

SourceAlliance for Clinical Trials in Oncology·JournalLung Cancer·TypeExperimental study·DateApr 20, 2026

Understanding the diverse chemokine signals in tumor microenvironment for advanced immunotherapy

Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 20, 2026

Targeting tumor supporting cells: Advancing CAR T success in pancreatic cancer

Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...

SourceUniversity of Pennsylvania·JournalCancer Immunology Research·TypeExperimental study·DateMar 31, 2026

Triple combination therapy before surgery helps boost immunity against aggressive soft tissue sarcomas

Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.

New study finds common blood pressure drug boosts cancer treatment

A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026

Engineered lipid nanoparticles reprogram immune metabolism for better mRNA vaccines

Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Materials·TypeExperimental study·DateMar 17, 2026

NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer

The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateMar 12, 2026

Overcoming ovarian cancer’s resistance to immunotherapy

A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...

SourceSanford Burnham Prebys·JournalCell Reports·TypeExperimental study·DateMar 5, 2026

Molecular target drives immunogenicity in cancer immunotherapy

Researchers have identified tyrosine phosphatase 1B (PTP1B) as a key molecular target in immunogenic cell death (ICD), a type of regulated cell death that activates the immune system against cancer cells. Two platinum-containing compounds, Pt-NHC and PlatinER, trigger ICD by blocking PTP1B's enzymatic activity.

SourceNational University of Singapore·JournalJournal of the American Chemical Society·TypeExperimental study·DateMar 5, 2026

Damon Runyon Cancer Research Foundation awards $3.2 million to innovative early-career scientists

The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...

Scientists report landmark “evolutionary double-bind” strategy to overcome treatment resistance in prostate cancer

Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.

Multiple myeloma: Established cancer drug reactivates immunotherapy

Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.

SourceTechnical University of Munich (TUM)·JournalBlood·TypeExperimental study·DateFeb 11, 2026

Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus

Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalClinical Cancer Research·DateFeb 10, 2026

New treatment approach boosts survival in young leukaemia patients

A recent clinical trial has shown that switching part of the standard chemotherapy protocol for a targeted immunotherapy significantly improves outcomes for young people living with acute lymphoblastic leukaemia (ALL). Nearly 89% of patients are still alive and cancer-free after three years of follow-up.

SourceSAHMRI·JournalHemaSphere·TypeExperimental study·DateFeb 1, 2026

Alliance Foundation Trials phase III PATINA study results published in the New England Journal of Medicine

The phase III PATINA study demonstrated that adding CDK4/6 inhibitor palbociclib to standard maintenance therapy significantly prolongs progression-free survival by more than 15 months compared to standard therapy alone. The study found a meaningful improvement in median PFS with no new signals.

SourceAlliance for Clinical Trials in Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 28, 2026